ALLOGRAFT AORTIC-VALVE REPLACEMENT - LONG-TERM FOLLOW-UP

Citation
Mf. Obrien et al., ALLOGRAFT AORTIC-VALVE REPLACEMENT - LONG-TERM FOLLOW-UP, The Annals of thoracic surgery, 60(2), 1995, pp. 65-70
Citations number
14
Categorie Soggetti
Surgery
ISSN journal
00034975
Volume
60
Issue
2
Year of publication
1995
Supplement
S
Pages
65 - 70
Database
ISI
SICI code
0003-4975(1995)60:2<65:AAR-LF>2.0.ZU;2-K
Abstract
Aortic valve replacement using an allograft aortic valve has been perf ormed on 804 patients. From December 1969 to May 1975, 124 patients re ceived a nonviable allograft valve sterilized by incubation with low-d ose antibiotics and stored for weeks by refrigeration at 4 degrees C ( series 1). From June 1975 to January 1994, 680 patients received viabl e allograft valves, now cryopreserved early within 2 hours of collecti on from transplant recipient donors, 6 hours for multiorgan donor valv es and 23 hours (mean) for autopsy valves from donor death. The 30-day mortality was 8.9% +/- 5% (95% confidence limits) for series I and 2. 8% +/- 1% (95% confidence limits) for series II. Actuarial patient sur vival including hospital mortality at 15 years was 56% +/- 5% for seri es I and 62% +/- 5% for series II. The probability of a thromboembolic event was low, freedom at 15 years being 95% +/- 1% for patients rece iving allografts with or without associated coronary bypass procedures and 81% +/- 5% for patients having allografts with other associated p rocedures (eg, mitral valve operations). Actuarial freedom from endoca rditis was similar for the two series, 91% +/- 3% (series I) and 94% /- 2% (series II) at 15 years. The freedom from valve incompetence, fr om reoperation for all causes, and from structural deterioration demon strated clearly the inferiority of the 4 degrees C stored allograft va lves. For structural deterioration as identified clinically, at reoper ation and at death, freedom from this event at 15 years was 45% +/- 6% for series I and 80% +/- 5% for series II (p value for the difference is 0). The attrition rate appears highest in young patients and in th ose not receiving a viable cryopreserved valve. An important immunolog ic response can be unfavorable in some young patients, producing valve deterioration. But for the majority of patients, the viable cryoprese rved allograft valve offers low morbidity with a good extended lifesty le and is superior to the 4 degrees C stored valve.